Advertisement

Detection of Minimal Residual Acute Lymphoblastic Leukemia by Immunological Marker Analysis: Possibilities and Limitations

  • J. J. M. van Dongen
  • H. Hooijkaas
  • H. J. Adriaansen
  • K. Hahlen
  • G. E. van Zanen
Part of the Developments in Oncology book series (DION, volume 45)

Abstract

The detection of small numbers of malignant cells is a major problem at diagnosis and during follow-up of malignancies (1). The possibilities and limitations of methods for the detection of minimal residual disease in general depend on their specificity (malignant cells have to be identified among many normal cells), sensitivity (detection limit of the method) and reproducibility. Although the method as such may have an excellent reproducibility, the cell sample may not always be representative for the whole cell population.

Keywords

Acute Lymphoblastic Leukemia Minimal Residual Disease Terminal Deoxynucleotidyl Transferase Lymphoblastic Lymphoma Malignant Counterpart 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Löwenberg B, Hagenbeek A(eds): Minimal residual disease in acute leukemia. Martinus Nijhoff Publishers, Boston, 1984.Google Scholar
  2. 2.
    Sonta SI, Sandberg AA: Chromosomes and causation of human cancer and leukemia: XXVIII. Value of detailed chromosome studies on large numbers of cells in CML. Am J Hematol 3, 121–126, 1977.PubMedGoogle Scholar
  3. 3.
    Benjamin D, Magrath IT, Douglass EC, Corash LM: Derivation of lymphoma cell lines from microscopically normal bone marrow in patients with undifferentiated lymphomas: Evidence of occult bone marrow involvement. Blood 61, 1017–1019, 1983.PubMedGoogle Scholar
  4. 4.
    Hittelman WN, Menegaz SD, McCredie KB, Keating MJ: Premature chromosome condensation studies in human leukemia: 5 Prediction of early relapse. Blood 64, 1067–1073, 1984.PubMedGoogle Scholar
  5. 5.
    Arnold A, Cossman J, Bakhshi A, Jaffe ES, Waldmann TA, Korsmeyer SJ: Immunoglobulingene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med 309, 1593–1599, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Cleary ML, Chao J, Warnke R, Sklar J: Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Nati Acad Sci USA 81, 593–597, 1984.CrossRefGoogle Scholar
  7. 7.
    Minden MD, Toyonaga B, Ha K, Yanagi Y, Chin B, Gelfand E, Mak T: Somatic rearrangement of T-cell antigen receptor gene in human T-cell malignancies. Proc Natl Acad Sci USA 82, 1224–1227, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    Janossy G, Bollum FJ, Bradstock KF, Ashley J: Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood 56, 430–441, 1980.PubMedGoogle Scholar
  9. 9.
    Foon KA, Schroff RW, Gale RP: Surface markers on leukemia and lymphoma cells: Recent advances. Blood 60, 1–19, 1982.PubMedGoogle Scholar
  10. 10.
    Knapp W(ed): Leukemia markers. Academic Press, London, 1981.Google Scholar
  11. 11.
    Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF(eds): Leucocyte typing. Springer Verlag, Berlin, 1984.Google Scholar
  12. 12.
    Ritz J, Pesando JM, Notis-McConarty J, Lazarus H, Schlossman SF: A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature 283, 583–585, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Van der Reijden HJ, van Wering ER, van de Rijn JM, Melief CJM, van ’t Veer MB, Behrendt H, von dem Borne AEGKr: Immunological typing of acute lymphoblastic leukaemia. Scand J Haematol 30, 356–366, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Greaves MF, Rao J, Hariri G, Verbi W, Catovsky D, Kung P, Goldstein G: Phenotypic heterogeneity and cellular origins of T cell malignancies. Leuk Res 5, 281–299, 1981.PubMedCrossRefGoogle Scholar
  15. 15.
    Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Valensi F, Dausset J, Flandrin G, Lemerle J, Schlossman SF: Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: Evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 57, 1105–1110, 1981.PubMedGoogle Scholar
  16. 16.
    Catovsky D, Linch DC, Beverley PCL: T cell disorders in haematological diseases. In: Janossy G(ed): Clinics in Haematology vol. 11, WB Saunders Company Ltd, London, p. 661–695, 1982.Google Scholar
  17. 17.
    Roper M, Crist WM, Metzgar R, Ragab AII, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci AA, Cooper MD: Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood 61, 830–837, 1983.PubMedGoogle Scholar
  18. 18.
    Chen PM, Chiang H, Chou CK, Hwang TS, Chiang BN, Greaves MF: Immunological classification of T-cell acute lymphoblastic leukaemia using monoclonal antibodies. Leuk Res 7, 339–348, 1983.PubMedCrossRefGoogle Scholar
  19. 19.
    Goldschneider I, Gregoire KE, Barton RW, Bollum FJ: Demonstration of terminal deoxynucleotidyl transferase in thymocytes by immunofluorescence. Proc Nati Acad Sci USA 74, 734–738, 1977.CrossRefGoogle Scholar
  20. 20.
    Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF: B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131, 244–250, 1983.PubMedGoogle Scholar
  21. 21.
    McKenzie IFC, Zola H: Monoclonal antibodies to B cells. Immunol Today 4, 10–15, 1983.CrossRefGoogle Scholar
  22. 22.
    Vogler LB, Crist WM, Bockman DE, Pearl ER, Lawton AR, Cooper MD: Pre-B-cell leukemia: A new phenotype of childhood lymphoblastic leukemia. N Engl J Med 298, 872–878, 1978.PubMedCrossRefGoogle Scholar
  23. 23.
    Hijmans W, Schuit HRE: Immunofluorescence studies on immunoglobulins in the lymphoid cells of human peripheral blood. Clin exp Immunol 11, 483–494, 1972.PubMedGoogle Scholar
  24. 24.
    Teodorescu M, Mayer EP: Surface immunoglobulin in immunoproliferative diseases. Annals Clin Lab Sci 8, 353–365, 1978.Google Scholar
  25. 25.
    Haynes BF, Mann DL, Hemler ME, Schroer JA, Shelhamer JH, Eisenbarth GS, Strominger JL, Thomas CA, Mostowski HS, Fauci AS: Characterization of a monoclonal antibody that defines an immunoregulatory T cell subset for immunoglobulin synthesis in humans. Proc Natl Acad Sci USA 77, 2914–2918, 1980.PubMedCrossRefGoogle Scholar
  26. 26.
    Vodinelich L, Tax W, Bai Y, Pegram S, Capel P, Greaves MF: A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors CT-ALL). Blood 62, 1108–1113, 1983.PubMedGoogle Scholar
  27. 27.
    Moore AL, Zusman J: Conditions enhancing the percentage and size of E rosettes formed by T lymphocytes. J Immunol Meth 23, 275–284, 1978.CrossRefGoogle Scholar
  28. 28.
    Janossy G, Prentice HG: T cell subpopulations, monoclonal antibodies and their therapeutic applications. In: Janossy G(ed): Clinics in Haematology vol. 11, WB Saunders Company Ltd, London, p. 631–660, 1982.Google Scholar
  29. 29.
    Hansen JA, Martin PJ, Beatty PG, Clark EA, Ledbetter JA: Human T lymphocyte cell surface molecules defined by the workshop monoclonal antibodies (‘T cell protocol’). In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF(eds): Leucocyte typing. Springer Verlag, Berlin, p. 195–212, 1984.Google Scholar
  30. 30.
    Fithian E, Kung P, Goldstein G, Rubenfeld M, Fenoglio C, Edelson R: Reactivity of Langerhans cells with hybridoma antibody. Proc Natl Acad Sci USA 78, 2541–2544, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Lampson LA, Levy R: Two populations of Ia-like molecules on a human B cell line. J Immunol 125, 293–299, 1980.PubMedGoogle Scholar
  32. 32.
    Falkenburg JHF, Jansen J, van der Vaart-Duinkerken N, Veenhof WFJ, Blotkamp J, Goselink HM, Parlevliet J, van Rood JJ: Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood 63, 1125–1132, 1984.PubMedGoogle Scholar
  33. 33.
    Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldmann TA: Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest 71, 301–313, 1983.PubMedCrossRefGoogle Scholar
  34. 34.
    Ford AM, Molgaard By, Greaves MF, Gould HJ: Immunoglobulin gene organisation and expression in haemopoietic stem cell leukaemia. EMBO J 2, 997–1001, 1983.PubMedGoogle Scholar
  35. 35.
    Tawa A, Hozumi N, Minden M, Mak TW, Gelfand EW: Rearrangement of the T-cell receptor β-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia of childhood. N Engl J Med 313, 1033–1037, 1985.PubMedCrossRefGoogle Scholar
  36. 36.
    Royer HD, Acuto O, Fabbi M, Tizard R, Ramachandran K, Smart JE, Reinherz EL: Genes encoding the Ti β subunit of the antigen/MHC receptor undergo rearrangement during intrathymic ontogeny prior to surface T3-Ti expression. Cell 39, 261–266, 1984.PubMedCrossRefGoogle Scholar
  37. 37.
    Kitchingman GR, Rovigatti U, Mauer AM, Melvin S, Murphy SB, Stass S: Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia. Blood 65, 725–729, 1985.PubMedGoogle Scholar
  38. 38.
    Rovigatti U, Mirro J, Kitchingman G, Dahl G, Ochs J, Murphy S, Stass S: Heavy chain immunoglobulin gene rearrangement in acute nonlymphocytic leukemia. Blood 63, 1023–1027, 1984.PubMedGoogle Scholar
  39. 39.
    Janossy G, Bollum FJ, Bradstock KF, McMichael A, Rapson N, Greaves MF: Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. J Immunol 123, 1525–1529, 1979.PubMedGoogle Scholar
  40. 40.
    Tidman N, Janossy G, Bodger M, Granger S, Kung PC, Goldstein G: Delineation of human thymocyte differentiation pathways utilizing double-staining techniques with monoclonal antibodies. Clin exp Immunol 45, 457–467, 1981.PubMedGoogle Scholar
  41. 41.
    Ligler FS, Vitetta ES, Smith RG, Himes JB, Uhr JW, Frenkel EP, Kettman JR: An immunologic approach for the detection of tumor cells in the peripheral blood of patients with malignant lymphoma; implications for the diagnosis of minimal disease. J Immunol 123, 1123–1126, 1979.PubMedGoogle Scholar
  42. 42.
    Samoszuk MK, Krailo M, Fan QH, Lukes RJ, Parker JW: Limitations of numerical ratios for defining monoclonality of immunoglobulin light chains in B-cell lymphomas. Diagnostic Immunol 3, 133–138, 1985.Google Scholar
  43. 43.
    Ault KA: Detection of small numbers of monoclonal B lymphocytes in the blood of patients with lymphoma. N Engl J Med 300, 1401–1405, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith BR, Weinberg DS, Robert NJ, Towle M, Luther E, Pinkus GS, Ault KA: Circulating monoclonal B lymphocytes in non-Hodgkin’s lymphoma. N Engl J Med 311, 1476–1481, 1984.PubMedCrossRefGoogle Scholar
  45. 45.
    Bollum FJ: Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. Blood 54, 1203–1215, 1979.PubMedGoogle Scholar
  46. 46.
    Janossy G, Tidman N, Papageorgiou ES, Kung PC, Goldstein G: Distribution of T lymphocyte subsets in the human bone marrow and thymus: An analysis with monoclonal antibodies. J Immunol 126: 1608–1613, 1981.PubMedGoogle Scholar
  47. 47.
    Desiderio SV, Yancopoulos GD, Paskind M, Thomas E, Boss MA, Landau N, Alt FW, Baltimore D: Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. Nature 311, 752–755, 1984.PubMedCrossRefGoogle Scholar
  48. 48.
    Janossy G, Hoffbrand AV, Greaves MF, Ganeshaguru K, Pain C, Bradstock KF, Prentice HG, Kay HEM, Lister TA: Terminal transferase enzyme assay and immunological membrane markers in the diagnosis of leukaemia: A multiparameter analysis of 300 cases. Br J Haematol 44, 221–234, 1980.PubMedCrossRefGoogle Scholar
  49. 49.
    Modak MJ, Mertelsmann R, Koziner B, Pahwa R, Moore MAS, Clarkson BD, Good RA: A micromethod for determination of terminal deoxynucleotidyl transferase (TdT) in the diagnostic evaluation of acute leukemias. J Cancer Res Clin Oncol 98, 91–104, 1980.PubMedCrossRefGoogle Scholar
  50. 50.
    Froehlich TW, Buchanan GB, Cornet JAM, Sartain PA, Smith RG: Terminal deoxynucleotidyl transferase-containing cells in peripheral blood: Implications for the surveillance of patients with lymphoblastic leukemia or lymphoma in remission. Blood 58, 214–220, 1981.PubMedGoogle Scholar
  51. 51.
    Buchanan GR, Smith HG: Detection of early relapse and minimal residual disease in children with acute lymphoblastic leukemia by enumeration of terminal deoxynucleotidyl transferase-positive cells in peripheral blood. In: Löwenberg B, Hagenbeek A(eds): Minimal residual disease in acute leukemia. Martinus Nijhoff Publishers, Boston, p. 83–95, 1984.Google Scholar
  52. 52.
    Bradstock KF, Janossy G, Hoffbrand AV, Ganeshaguru K, Llewellin P, Prentice HG, Bollum FJ: Immunofluorescent and biochemical studies of terminal deoxynucleotidyl transferase in treated acute leukaemia. Br J Haematol 47, 121–131, 1981.PubMedCrossRefGoogle Scholar
  53. 53.
    Kalwinsky DK, Weatherred WH, Dahl GV, Bowman WP, Melvin SL, Coleman MS, Bollum FJ: Clinical utility of initial terminal deoxynucleotidyl transferase determinations in childhood acute leukemias. Cancer Res 41, 2877–2881, 1981.PubMedGoogle Scholar
  54. 54.
    Hutton JJ, Coleman MS, Moffitt S, Greenwood ME, Holland P, Lampkin B, Kisker T, Krill C, Kastelic JE, Valdez L, Bollum FJ: Prognostic significance of terminal transferase activity in childhood acute lymphoblastic leukemia: A prospective analysis of 164 patients. Blood 60, 1267–1276, 1982.PubMedGoogle Scholar
  55. 55.
    Barr RD, Koekebakker M, Sarin PS: Early relapse of acute lymphoblastic leukemia is not predictable by serial biochemical assays of terminal transferase activity in cells from peripheral blood. Leuk Res 8, 351–354, 1984.PubMedCrossRefGoogle Scholar
  56. 56.
    Hooijkaas H, van Dongen JJM, Hählen K, van Zanen GE: Immunological characterisation of cells in cerebrospinal fluid from patients with lymphoid malignancies. Lancet i, 518–519, 1984.CrossRefGoogle Scholar
  57. 57.
    Hooijkaas H, van Dongen JJM, Hählen K, van Zanen GE: Identification and monitoring of terminal deoxynucleotidyl transferase positive cells in the cerebrospinal fluid of children with lymphoid malignancies. In: Peeters H(ed): Protides of the biological fluids, Pergamon Press, Oxford, p. 875–878, 1984.Google Scholar
  58. 58.
    Barr RD, Koekebakker M: Detection of circulating ‘terminal transferase-positive’ cells does not predict relapse in acute lymphoblastic leukemia. Leuk Res 8, 1051–1055, 1984.PubMedCrossRefGoogle Scholar
  59. 59.
    Koekebakker M, Barr RD: Demonstration of terminal deoxynucleotidyl transferase in single cells by indirect immunofluorescence-A methodological reappraisal. Leuk Res 7, 237–241, 1983.PubMedCrossRefGoogle Scholar
  60. 60.
    Bradstock KF, Papageorgiou ES, Janossy G, Hoffbrand AV, Willoughby ML, Roberts PD, Bollum FJ: Detection of leukaemic lymphoblasts in CSF by immunofluorescence for terminal transferase. Lancet i, 1144, 1980.CrossRefGoogle Scholar
  61. 61.
    Bradstock KF, Papageorgiou ES, Janossy G: Diagnosis of meningeal involvement in patients with acute lymphoblastic leukemia: Immunofluorescence for terminal transferase. Cancer 47, 2478–2481, 1981.PubMedCrossRefGoogle Scholar
  62. 62.
    Casper JT, Lauer SJ, Kirchner PA, Gottschall JL, Camitta BM: Evaluation of cerebrospinal fluid mononuclear cells obtained from children with acute lymphocytic leukemia: Advantages of combining cytomorphology and terminal deoxynucleotidyl transferase. Am J Clin Pathol 80, 666–670, 1983.PubMedGoogle Scholar
  63. 63.
    Greaves M, Delia D, Janossy G, Rapson N, Chessells J, Woods M, Prentice G: Acute lymphoblastic leukaemia associated antigen. IV. Expression on non-leukaemic ‘lymphoid’ cells. Leuk Res 4, 15–32, 1980.PubMedCrossRefGoogle Scholar
  64. 64.
    Greaves MF, Hariri G, Newman RA, Sutherland DR, Ritter MA, Ritz J: Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood 61, 628–639, 1983.PubMedGoogle Scholar
  65. 65.
    Ryan DH, Mitchell SJ, Hennessy LA, Bauer KD, Horan PK, Cohen HJ: Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry. J Immunol Meth 74, 115–128, 1984.CrossRefGoogle Scholar
  66. 66.
    Braun MP, Martin PJ, Ledbetter JA, Hansen JA: Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens. Blood 61, 718–725, 1983.PubMedGoogle Scholar
  67. 67.
    Neudorf SML, LeBien TW, Kersey JH: Characterization of thymocytes expressing the common acute lymphoblastic leukemia antigen. Leuk Res 8, 173–179, 1984.PubMedCrossRefGoogle Scholar
  68. 68.
    Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM, Schlossman SF: Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood 58, 648–652, 1981.PubMedGoogle Scholar
  69. 69.
    Veerman AJP, Huismans DR, van Zantwijk CH, de Waal FC: Immunologische bepaling van oppervlaktedeterminanten op cellen in de liquor cerebrospinalis van kinderen met acute lymfatische leukemie. Ned Tijdschr Geneeskd 128, 100–103, 1984.PubMedGoogle Scholar
  70. 70.
    Greaves M, Paxton A, Janossy G, Pain C, Johnson S, Lister TA: Acute lymphoblastic leukaemia associated antigen. III. Alterations in expression during treatment and in relapse. Leuk Res 4, 1–14, 1980.PubMedCrossRefGoogle Scholar
  71. 71.
    McMichael AJ, Pilch JR, Galfré G, Mason DY, Fabre JW, Milstein C: A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody. Eur J Immunol 9, 205–210, 1979.PubMedCrossRefGoogle Scholar
  72. 72.
    McMillan EM, Brubaker DB, Peters S, Jackson I, Beeman K, Wasik R, Stoneking LE, Resler DR: Demonstration of cells bearing the OKT6 determinant in human tonsil and lymph node. Cancer Immunol Immunother 15, 221–226, 1983.PubMedCrossRefGoogle Scholar
  73. 73.
    De Bruin HG, Astaldi A, Leupers T, van de Griend RJ, Dooren LJ, Schellekens PThA, Tanke HJ, Roos M, Vossen JM: T lymphocyte characteristics in bone marrow-transplanted patients. II. Analysis with monoclonal antibodies. J Immunol 127, 244–251, 1981.PubMedGoogle Scholar
  74. 74.
    Kluin-Nelemans HC, Bolhuis RLH, Löwenberg B, Campana D, Sizoo W: Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. Scand J Haematol, in press.Google Scholar
  75. 75.
    Van Dongen JJM, Hooijkaas H, Hählen K, Benne K, Bitter WM, van der Linde-Preesman AA, Tettero ILM, van de Rijn M, Hilgers J, van Zanen GE, Hagemeijer A: Detection of minimal residual disease in TdT positive T cell malignancies by double immunofluorescence staining. In: Löwenberg B, Hagenbeek A(eds): Minimal residual disease in acute leukemia. Martinus Nijhoff Publishers, Boston, p. 67–81, 1984.Google Scholar
  76. 76.
    Neudorf SML, LeBien TW, Bollum F, Kersey JH: Double fluorochrome analysis of human bone marrow lymphoid cells: Studies with terminal transferase and anti-T-cell monoclonal anti-bodies. Exp Hematol 12, 69–73, 1984.PubMedGoogle Scholar
  77. 77.
    Bernard A, Raynal B, Lemerle J, Boumsell L: Changes in surface antigens on malignant T cells from lymphoblastic lymphomas at relapse: An appraisal with monoclonal antibodies and microfluorometry. Blood 59, 809–815, 1982.PubMedGoogle Scholar
  78. 78.
    Bradstock KF, Janossy G, Tidman N, Papageorgiou ES, Prentice HG, Willoughby M, Hoffbrand AV: Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 5, 301–309, 1981.PubMedCrossRefGoogle Scholar
  79. 79.
    Donlon JA, Jaffe ES, Braylan RC: Terminal deoxynucleotidyl transferase activity in malignant lymphomas. N Engl J Med 297, 461–464, 1977.PubMedCrossRefGoogle Scholar
  80. 80.
    Kung PC, Long JC, McCaffrey RP, Ratliff RL, Harrison TA, Baltimore D: Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma. Am J Med 64, 788–794, 1978.PubMedCrossRefGoogle Scholar
  81. 81.
    Braziel RM, Keneklis T, Donlon JA, Hsu SM, Cossman J, Bollum FJ, Jaffe ES: Terminal deoxynucleotidyl transferase in non-Hodgkin’s lymphoma. Am J Clin Pathol 80, 655–659, 1983.PubMedGoogle Scholar
  82. 82.
    Van Dongen JJM, Hooijkaas H, Comans-Bitter M, Hählen K, de Klein A, van Zanen GE, van ’t Veer MB, Abels J, Benner R: Human bone marrow cells positive for terminal deoxynucleotidyl transferase (Td1), HLA-DR, and a T cell marker may represent prothymocytes. J Immunol 135, 3144–3150, 1985.PubMedGoogle Scholar
  83. 83.
    Van Dongen JJM, Hooijkaas H, Comans-Bitter WM, Benne K, van Os TM, de Josselin de Jong J: Triple immunological staining with colloidal gold, fluorescein and rhodamine as labels. J Immunol Meth 80, 1–6, 1985.CrossRefGoogle Scholar
  84. 84.
    Krolick KA, Uhr JW, Vitetta ES: Selective killing of leukaemia cells by antibody-toxin conjugates: Implications for autologous bone marrow transplantation. Nature 295, 604–605, 1982.PubMedCrossRefGoogle Scholar
  85. 85.
    Hagenbeek A, Martens ACM: Detection of minimal residual disease in acute leukemia: Possibilities and limitations. Eur J Cancer Clin Oncol 21, 389–395, 1985.PubMedCrossRefGoogle Scholar
  86. 86.
    Bradstock KF, Kerr A: Immunological detection of covert leukaemic spread in mediastinal T-cell lymphoblastic lymphoma. Leuk Res 9, 905–911, 1985.PubMedCrossRefGoogle Scholar
  87. 87.
    Weinstein HJ, Vance ZB, Jaffe N, Buell D, Cassady JR, Nathan DG: Improved prognosis for patients with mediastinal lymphoblastic lymphoma. Blood 53, 687–694, 1979.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1986

Authors and Affiliations

  • J. J. M. van Dongen
  • H. Hooijkaas
  • H. J. Adriaansen
  • K. Hahlen
  • G. E. van Zanen

There are no affiliations available

Personalised recommendations